Viewing data from:

LIDOCAINE HYDROCHLORIDE

ANDA

LIDOCAINE HYDROCHLORIDE | A214336 | ASPIRO PHARMA LTD

2 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: XYLOCAINE(TE code: AP)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 9 NDCs

Highest NADAC/Unit

$0.0878

per ml

Lowest NADAC/Unit

$0.0542

per ml

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
31722021731LIDOCAINE HCL 2% VIAL	$0.0878	ML	Generic	—	2026-06-17
72603074425LIDOCAINE HCL 2% 400 MG/20 ML	$0.0878	ML	Generic	—	2026-06-17
72603082510LIDOCAINE HCL 2% 1,000 MG/50 ML	$0.0878	ML	Generic	—	2026-06-17
31722021733LIDOCAINE HCL 2% VIAL	$0.0878	ML	Generic	—	2026-06-17
31722011631LIDOCAINE HCL 1% VIAL	$0.0700	ML	Generic	—	2026-06-17
31722011634LIDOCAINE HCL 1% VIAL	$0.0700	ML	Generic	—	2026-06-17

Showing 6 of 9 NDCs.

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain7 active DMFs4 inactive

7 active API suppliers hold Drug Master Files for this ingredient.

MOEHS IBERICA SLLIDOCAINE HYDROCHLORIDE

DMF 58761985

DELTA SYNTHETIC CO LTDLIDOCAINE HYDROCHLORIDE

DMF 113381995

CAMBREX KARLSKOGA ABLIDOCAINE HYDROCHLORIDE

DMF 195312006

MAHENDRA CHEMICALSLIDOCAINE HYDROCHLORIDE USP

DMF 240512010

SWATI SPENTOSE PRIVATE LTDLIDOCAINE HYDROCHLORIDE USP

DMF 259632012

APEX HEALTHCARE LTDLIDOCAINE HYDROCHLORIDE USP

DMF 391392023

SHIJIAZHUANG CANSAV PHARMACEUTICAL TECHNOLOGY CO LTDLIDOCAINE HYDROCHLORIDE

DMF 408142024

HOECHST AGInactiveLIDOCAINE HYDROCHLORIDE AND BASE(BULK

DMF 59211985

GUFIC BIOSCIENCES LTDInactiveLIDOCAINE HYDROCHLORIDE

DMF 174832004

KONDUSKAR LABORATORIES PVT LTDInactiveLIDOCAINE HYDROCHLORIDE USP

DMF 240562010

APEX HEALTHCARE LTDInactiveLIDOCAINE HYDROCHLORIDE USP

DMF 343072020

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — 1%

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Nov 8, 2021

No patent or exclusivity listings for this strength.

#002 — 2%

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Dec 13, 2023